Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024

Benzinga · Nov 14 21:05

- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting, taking place November 15-19, 2024, in San Diego, California.

Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the AASLD website. Full analyses will be available following their presentation within the Publications & Presentation section on Mirum's website.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024

Risk Disclaimer